Glenmark Pharmaceuticals begins Phase II clinical trail
To evaluate investigational infusion therapy GBR 500 in patients
Glenmark Pharmaceuticals announced the enrolment of the first patient in a multicentre Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab (GBR 500) in patients with relapsing remitting multiple sclerosis (RRMS)Powered by Capital Market - Live News